Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Find out how Carterra Inc.’s Vega HT-SPR platform could redefine primary screening and reshape early drug discovery workflows.
Peer-reviewed data puts Brightseed’s BioMetaControl under the clinical microscope. Find out what this trial means for GLP-1 companions and metabolic care.
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks […]
insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical […]